Landscape of KRAS, BRAF, PIK3CA Genes Mutations and Clinical Features of EBV-Associated and MSI Gastric Cancer

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Тек жазылушылар үшін

Аннотация

Personalization of gastric cancer treatment is an urgent problem due to clinical heterogeneity and aggressive course of the disease. In 2014, Cancer Genome Atlas researchers divided gastric cancers into four subtypes based on molecular characteristics: Epstein–Barr virus positive (EBV+), microsatellite instability (MSI), chromosomal instability, genomically stable. To date, there is no single method for detecting chromosomal instability and genomically stable subtypes, while MSI analysis and EBV assessment are used in routine practice and are of the greatest clinical importance. We analyzed 159 gastric cancer samples for the presence of MSI, EBV DNA, and somatic mutations in codons 12–13 (exon 2), 61 (exon 3), and 146 (exon 4) of the KRAS gene, codons 597–601 (exon 15) of the BRAF gene and codons 542–546 (exon 9), 1047–1049 (exon 20) of the PIK3CA gene. As a result, the EBV+ gastric cancer was detected in 8.2% of samples, MSI – in 13.2%. MSI and EBV+ were found to be mutually exclusive. The mean age of patients with EBV+ and MSI cancers was 54.8 and 62.1 years, respectively. In 92.3% of EBV+ cancer was detected in men, of which 76.2% were older than 50 years. diffuse and intestinal adenocarcinomas in EBV+ cancer accounted for 6 (46.2%) and 5 (38.5%) cases, respectively. MSI occurred in almost equal proportions in men and women (n = 10; 47.6%, n = 11; 52.4%), with a predominance of intestinal histological type (71.4%) and lesion of the lesser curvature (28.6%). One case of EBV+ cancer was diagnosed with the E545K variant in the PIK3CA gene. A combination of variants in the KRAS and PIK3CA genes was found in all MSI cases. The EBV+ subtype was associated with a better prognosis. Overall five-year survival rates for MSI and EBV+ cancers were 100.0 and 54.7%, respectively.

Авторлар туралы

A. Danishevich

Moscow Clinical Scientific and Practical Center named after A.S. Loginov of Moscow Department of Health

Хат алмасуға жауапты Автор.
Email: danisham7@gmail.com
Russia, 111123, Moscow

N. Pospehova

Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

Email: danisham7@gmail.com
Russia, 115478 , Moscow

A. Stroganova

Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

Email: danisham7@gmail.com
Russia, 115478 , Moscow

D. Golovina

Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

Email: danisham7@gmail.com
Russia, 115478 , Moscow

M. Nikulin

Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

Email: danisham7@gmail.com
Russia, 115478 , Moscow

A. Kalinin

Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

Email: danisham7@gmail.com
Russia, 115478 , Moscow

S. Nikolaev

Moscow Clinical Scientific and Practical Center named after A.S. Loginov of Moscow Department of Health

Email: danisham7@gmail.com
Russia, 111123, Moscow

I. Stilidi

Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

Email: danisham7@gmail.com
Russia, 115478 , Moscow

L. Lyubchenko

National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation; Lopatkin Scientific Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation

Email: danisham7@gmail.com
Russia, 125284, Moscow; Russia, 105425, Moscow

Әдебиет тізімі

  1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J. Clinicians. 71, 209–249.
  2. Oba K., Paoletti X., Alberts S., Bang Y.J., Benedetti J., Bleiberg H., Catalano P., Lordick F., Michiels S., Morita S., Ohashi Y., Pignon J.P., Rougier P., Sasako M., Sakamoto J., Sargent D., Shitara K., Van Cutsem E., Buyse M., Byrzykowski T., GASTRIC group (2013) Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J. Natl. Cancer Inst. 105, 1600–1607.
  3. Dicken B.J., Bigam D.L., Cass C., Mackey J.R., Joy A.A., Hamilton S.M. (2005) Gastric adenocarcinoma: review and considerations for future directions. Ann. Surgery. 241, 27–39.
  4. Каприн А.Д., Старинский В.В., Шахзадова А.О. (2020) Злокачественные новообразования в России в 2019 году. Москва: МНИОИ им. П.А. Герцена − филиал ФГБУ “НМИЦ радиологии” Минздрава России.
  5. Lauren P. (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol. Microbial. Scandinavica. 64, 31–49.
  6. Tan P., Yeoh K.G. (2015) Genetics and molecular pathogenesis of gastric adenocarcinoma. Gastroenterology. 149, 1153–1162.
  7. Bonequi P., Meneses-González F., Correa P., Rabkin C.S., Camargo M.C. (2013) Risk factors for gastric cancer in Latin-America: a meta-analysis. Cancer Causes Control. 24, 217‒231.
  8. Strumylaite L., Zickute J., Dudzevicius J., Dregval L. (2006) Salt-preserved foods and risk of gastric cancer. Medicina (Kaunas, Lithuania), 42, 164–170.
  9. González C.A., Pera G., Agudo A., Palli D., Krogh V., Vineis P., Tumino R., Panico S., Berglund G., Simán H., Nyrén O., Agren A., Martinez C., Dorronsoro M., Barricarte A., Tormo M.J., Quiros J.R., Allen N., Bingham S., Day N., Miller A., Nagel G., Boeing H., Overland K., Tjonneland A., Bueno-De-Mesquita H.B., Boshuizen H.C., Peeters P., Numans M., Clavel-Chapelon F., Helen I., Agapitos E., Lund E., Fahey M., Saracci R., Kaaks R., Riboli E. (2003) Smoking and the risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Internat. J. Cancer. 107, 629–634.
  10. Plummer M., Franceschi S., Vignat J., Forman D., De Martel C. (2015) Global burden of gastric cancer attributable to Helicobacter pylori. Internat. J. Cancer. 136, 487–490.
  11. Uozaki H., Fukayama M. (2008) Epstein–Barr virus and gastric carcinoma – viral carcinogenesis through epigenetic mechanisms. Int. J. Clin. Exp. Pathol. 1, 198‒216.
  12. Bae J.M., Kim E.H. (2016) Epstein–Barr Virus and gastric cancer risk: a meta-analysis with meta-regression of case-control studies. J. Prev. Med. Public Health. 49, 97‒107.
  13. Assumpção P., Araújo T., Khayat A., Santos S., Barra W., Ishak G., Santos S., Barra W., Felipe Acioli J., Rossi B. Assumpção P. (2020) Hereditary gastric cancer: three rules to reduce missed diagnoses. World J. Gastroenterol. 26, 1382‒1393.
  14. The Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 513, 202–209.
  15. Matsusaka K., Kaneda A., Nagae G., Ushiku T., Kikuchi Y., Hino R., Uozaki H., Seto Y., Takada K., Aburatani H., Fukayama M. (2011) Classification of Epstein–Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res. 71, 7187–7197.
  16. Zhao J., Liang Q., Cheung K.F., Kang W., Lung R.W.M., Tong J.H.M., To K.F., Sung J.J.Y., Yu J. (2013) Genome-wide identification of Epstein–Barr virus-driven promoter methylation profiles of human genes in gastric cancer cells. Cancer. 119, 304–312.
  17. Kandoth C., McLellan M.D., Vandin F., Ye K., Niu B., Lu C., Xie M., Zhang Q., McMichael J.F., Wyczalkowski M.A., Leiserson M.D.M., Miller C.A., Welch J.S., Walter M.J., Wendl M.C., Ley T.J., Wilson R.K., Raphael B.J., Ding L. (2013) Mutational landscape and significance across 12 major cancer types. Nature. 502, 333–339.
  18. Astolfi A., Fiore M., Melchionda F., Indio V., Bertuccio S.N., Pession A. (2019) BCOR involvement in cancer. Epigenomics. 11, 835‒855.
  19. Hoadley K.A., Yau C., Wolf D.M., Cherniack A.D., Tamborero D., Zou L., Ng S., Leiserson M. D. M., Niu B., McLellan M.D., Uzunangelov V., Zhang J., Kandoth C., Akbani R., Shen H., Omberg L., Chu A., Margolin A.A., Veer L.A.J., Lopez-Bigas N., Laird P.W., Raphael B.J., Ding L., Robertson A. G., Lauren A.B., Mills G.B., Weinstein J.N., Waes C.V., Chen Z., Collisson E.A., Cancer Genome Atlas Research Network, Benz C.C., Perou C.M., Stuart J.M. (2014) Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 158, 929–944.
  20. Böger C., Krüger S., Behrens H.M., Bock S., Haag J., Kalthoff H., Röcken C. (2017) Epstein–Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations. Ann. Oncol. 28, 1005–1014.
  21. Dong M., Wang H.Y., Zhao X.X., Chen J.N., Zhang Y.W., Huang Y., Xue L., Li H.G., Du H., Wu X.Y., Shao C.K. (2016) Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein–Barr virus-associated gastric carcinoma. Hum. Pathol. 53, 25–34.
  22. Derks S., Liao X., Chiaravalli A.M., Xu X., Camargo M.C., Solcia E., Sessa F., Fleitas T., Freeman G.J., Rodig S.J., Rabkin C.S., Bass A.J. (2016) Abundant PD-L1 expression in Epstein–Barr virus-infected gastric cancers. Oncotarget. 7, 32925–32932.
  23. Camargo M.C., Kim K.M., Matsuo K., Torres J., Liao L.M., Morgan D.R., Michel A., Waterboer T., Zabaleta J., Dominguez R.L., Yatabe Y., Kim S., Rocha-Guevara E.R., Lissowska J., Pawlita M., Rabkin C.S. (2016) Anti-Helicobacter pylori antibody profiles in Epstein–Barr virus (EBV)-positive and EBV-negative gastric cancer. Helicobacter. 21, 153–157.
  24. Yanagi A., Nishikawa J., Shimokuri K., Shuto T., Takagi T., Takagi F., Kobayashi Y., Yamamoto M., Miura O., Yanai H., Suehiro Y., Yamasaki T., Yoshiyama H., Sakaida I. (2019) Clinicopathologic characteristics of Epstein–Barr virus-associated gastric cancer over the past decade in Japan. Microorganisms. 7, 305.
  25. van Beek J., zur Hausen A., Kranenbarg E.K., van de Velde C.J.H., Middeldorp J.M., van den Brule A.J.C., Meijer C.J.L.M., Bloemena E. (2004) EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J. Clin. Oncol. : Official J. Am. Soc. Clin. Oncol. 22, 664–670.
  26. Sohn B.H., Hwang J.E., Jang H.J., Lee H.S., Oh S.C., Shim J.J., Lee K.W., Kim E.H., Yim S.Y., Lee S.H., Cheong J.H., Jeong W., Cho J.Y., Kim J., Chae J., Lee J., Kang W.K., Kim S., Noh S.H., Ajani J.A., Lee J.S. (2017) Clinical significance of four molecular subtypes of gastric cancer identified by The Cancer Genome Atlas Project. Clin. Cancer Res. 23, 4441–4449.
  27. Lee H.S., Chang M.S., Yang H.K., Lee B.L., Kim W.H. (2004) Epstein–Barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with Epstein–Barr virus-negative carcinoma. Clin. Cancer Res. 10, 1698–1705.
  28. Choi Y.Y., Bae J.M., An J.Y., Kwon I.G., Cho I., Shin H.B., Eiji T., Aburahmah M., Kim H. I., Cheong J.H., Hyung W.J., Noh S.H. (2014) Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis. J. Surg. Oncol. 110, 129–135.
  29. Smyth E.C., Wotherspoon A., Peckitt C., Gonzalez D., Hulkki-Wilson S., Eltahir Z., Fassan M., Rugge M., Valeri N., Okines A., Hewish M., Allum W., Stenning S., Nankivell M., Langley R., Cunningham D. (2017) Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial. JAMA Oncol. 3, 1197–1203.
  30. Choi Y.Y., Cheong J.H. (2019) Comment on ‘To Treat, or Not to Treat, That is the Question: biomarker-guided adjuvant chemotherapy for stage ii and iii gastric cancer’. Ann. Surgery. 270, e40–e41.
  31. Shin S.J., Kim S.Y., Choi Y.Y., Son T., Cheong J.-H., Hyung W.J., Noh S.H., Park C.-G., Kim H.-I. (2019) Mismatch repair status of gastric cancer and its association with the local and systemic immune response. Oncologist. 24, 835–844.
  32. Zhu L., Li Z., Wang Y., Zhang C., Liu Y., Qu X. (2015) Microsatellite instability and survival in gastric cancer: a systematic review and meta-analysis. Mol. Clin. Oncol. 3, 699–705.
  33. Latham A., Srinivasan P., Kemel Y., Shia J., Bandlamudi C., Mandelker D., Middha S., Hechtman J., Zehir A., Dubard-Gault M., Tran C., Stewart C., Sheehan M., Penson A., DeLair D., Yaeger R., Vijai J., Mukherjee S., Galle J., Dickson M.A., Janjigian Y., O’Reilly E.M., Segal N., Saltz L.B., Reidy-Lagunes D., Varghese A.M., Bajorin D., Carlo M.I., Cadoo K., Walsh M.F., Weiser M., Aguilar J.G., Klimstra D.S., Diaz L.A., Baselga J., Zhang L., Ladanyi M., Hyman D.M., Solit D.B., Robson M.E., Taylor B.S., Offit K., Berger M.F., Stadler Z.K. (2019) Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer. J. Clin. Oncol. 37, 286–295.
  34. Wu M.S., Sheu J.C., Shun C.T., Lee W.J., Wang J.T., Wang T.H., Cheng A.L., Lin J.T. (1997) Infrequent hMSH2 mutations in sporadic gastric adenocarcinoma with microsatellite instability. Cancer Lett. 112, 161–166.
  35. Leite M., Corso G., Sousa S., Milanezi F., Afonso L.P., Henrique R., Soares J.M., Castedo S., Carneiro F., Roviello F., Oliveira C., Seruca R. (2011) MSI phenotype and MMR alterations in familial and sporadic gastric cancer. Internat. J. Cancer. 128, 1606–1613.
  36. Wang K., Kan J., Yuen S.T., Shi S.T., Chu K.M., Law S., Chan T.L., Kan Z., Chan A.S.Y., Tsui W.Y., Lee S.P., Ho S.L., Chan A.K.W., Cheng G.H.W., Roberts P.C., Rejto P.A., Gibson N.W., Pocalyko D.J., Mao M., Xu J., Leung S.Y. (2011) Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat. Genet. 43, 1219–1223.
  37. Corso G., Velho S., Paredes J., Pedrazzani C., Martins D., Milanezi F., Pascale V., Vindigni C., Pinheiro H., Leite M., Marrelli D., Sousa S., Carneiro F., Oliveira C., Roviello F., Seruca R. (2011) Oncogenic mutations in gastric cancer with microsatellite instability. Eur. J. Cancer. 47, 443–451.
  38. Wang K., Yuen S.T., Xu J., Lee S.P., Yan H.H.N., Shi S.T., Siu H.C., Deng S., Chu K.M., Law S., Chan K.H., Chan A.S.Y., Tsui W.Y., Ho S.L., Chan A.K.W., Man J.L.K., Foglizzo V., Ng M.K., Chan A.S., Ching Y.P., Leung S.Y. (2014) Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat. Genet. 46, 573–582.
  39. Kim M.S., Oh J.E., Kim Y.R., Park S.W., Kang M.R., Kim S.S., Ahn C.H., Yoo N.J., Lee S.H. (2010) Somatic mutations and losses of expression of microRNA regulation-related genes AGO2 and TNRC6A in gastric and colorectal cancers. J. Pathol. 221, 139–146.
  40. Bernal M., Ruiz-Cabello F., Concha A., Paschen A., Garrido F. (2012) Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes. Cancer Immunol., Immunother. 61, 1359–1371.
  41. Chao J., Fuchs C.S., Shitara K., Tabernero J., Muro K., Van Cutsem E., Bang Y.J., De Vita F., Landers G., Yen C.J., Chau I., Elme A., Lee J., Özgüroǧlu M., Catenacci D., Yoon H.H., Chen E., Adelberg D., Shih C.S., Shah S., Bhagia P., Waingberg Z.A. (2021) Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 7, 895–902.
  42. Polom K., Marano L., Marrelli D., De Luca R., Roviello G., Savelli V., Tan P., Roviello F. (2018) Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. Br. J. Surgery. 105, 159–167.
  43. Mathiak M., Warneke V.S., Behrens H.M., Haag J., Böger C., Krüger S., Röcken C. (2017) Clinicopathologic characteristics of microsatellite instable gastric carcinomas revisited: urgent need for standardization. Appl. Immunohistochem. Mol. Morphol. 25, 12–24.
  44. Hause R.J., Pritchard C.C., Shendure J., Salipante S.J. (2016) Classification and characterization of microsatellite instability across 18 cancer types. Nat. Med. 22, 1342–1350.
  45. Lengauer C., Kinzler K.W., Vogelstein B. (1998) Genetic instabilities in human cancers. Nature. 396, 643–649.
  46. Ottini L., Falchetti M., Lupi R., Rizzolo P., Agnese V., Colucci G., Bazan V., Russo A. (2006) Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Ann. Oncol. 17(Suppl. 7), vii97–vii102.
  47. Jung E.J., Jung E.J., Min S.Y., Kim M.A., Kim W.H. (2012) Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma. Hum. Pathol. 43, 1559–1566.
  48. Xie L., Su X., Zhang Lin, Yin X., Tang L., Zhang Xiuhua, Xu Y., Gao Z., Liu K., Zhou M., Gao B., Shen D., Zhang L., Ji A., Gavine P.R., Zhang J., Kilgour E., Zhang X., Ji Q. (2013) FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin. Cancer Res. 19, 2572–2583.
  49. Dulak A.M., Schumacher S.E., Van Lieshout J., Imamura Y., Fox C., Shim B., Ramos A.H., Saksena G., Baca S.C., Baselga J., Tabernero J., Barretina J., Enzinger P.C., Corso G., Roviello F., Lin L., Bandla S., Luketich J.D., Pennathur A., Meyerson M., Ogino S., Shivdasani R.A., Beer D.G., Godfrey T.E., Beroukhim R., Bass A.J. (2012) Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res. 72, 4383–4393.
  50. Deng N., Goh L.K., Wang H., Das K., Tao J., Tan I.B., Zhang S., Lee M., Wu J., Lim K.H., Lei Z., Goh G., Lim Q.Y., Tan A.L.K., Poh D.Y.S., Riahi S., Bell S., Shi M.M., Linnartz R., Zhu F., Yeoh K.G., Toh H.C., Yong W.P., Cheong H.C., Rha S.Y., Boussioutas A., Grabsch H., Rozen S., Tan P. (2012) A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 61, 673–684.
  51. Palanisamy N., Ateeq B., Kalyana-Sundaram S., Pflueger D., Ramnarayanan K., Shankar S., Han B., Cao Q., Cao X., Suleman K., Kumar-Sinha C., Dhanasekaran S.M., Chen Y.B., Esgueva R., Banerjee S., Lafargue C.J., Siddiqui J., Demichelis F., Moeller P., Bismar T.A., Kuefer R., Fullen D.R., Johnson T.M., Greenson J.K., Giordano T.J., Tan P., Tomlins S.A., Varambally S., Rubin M.A., Maher C.A., Chinnaiyan A.M. (2010) Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat. Med. 16, 793–798.
  52. Yu H., Jove R. (2004) The STATs of cancer – new molecular targets come of age. Nat. Rev. Cancer. 4, 97–105.
  53. The Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature. 487, 330–337.
  54. Medina P.P., Nolde M., Slack F.J. (2010) OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature. 467, 86–90.
  55. Pfeffer S.R., Yang C.H., Pfeffer L.M. (2015) The role of miR-21 in cancer. Drug Dev. Res. 76, 270–277.
  56. Deyhimi P., Kalantari M. (2014) Study of Epstein-Barr virus expression in Burkitt’s lymphoma by polymerase chain reaction and in situ hybridization: a study in Iran. Dental Res. J. 11, 380–385.
  57. Tavakoli A., Monavari S.H., Solaymani Mohammadi F., Kiani S.J., Armat S., Farahmand M. (2020) Association between Epstein–Barr virus infection and gastric cancer: a systematic review and meta-analysis. BMC Cancer. 20, 493.
  58. Suraweera N., Duval A., Reperant M., Vaury C., Furlan D., Leroy K., Seruca R., Iacopetta B., Hamelin R. (2002) Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology. 123, 1804–1811.
  59. Polom K., Marrelli D., Roviello G., Pascale V., Voglino C., Vindigni C., Generali D., Roviello F. (2018) PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene. Adv. Clin. Exp. Med. 7, 963–969.
  60. Van Grieken N.C.T., Aoyma T., Chambers P.A., Bottomley D., Ward L.C., Inam I., Buffart T.E., Das K., Lim T., Pang B., Zhang S.L., Tan I.B., Carvalho B., Heideman D.A.M., Miyagi Y., Kameda Y., Arai T., Meijer G.A., Tsuburaya A., Tan P., Yoshikawa T., Grabsch H.I. (2013) KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study. Br. J. Cancer. 108, 1495–1501.
  61. Barbi S., Cataldo I., De Manzoni G., Bersani S., Lamba S., Mattuzzi S., Bardelli A., Scarpa A. (2010) The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. J. Exp. Clin. Cancer Res. 29, 32.
  62. Lu W., Wei H., Li M., Wang H., Liu L., Zhang Q., Liu L., Lu S. (2015) Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer. Mol. Med. Rep. 1, 1219–1224.
  63. Бесова Н. С., Трякин А. А., Артамонова Е. В., Болотина Л. В., Калинин А. Е., Кононец П. В., Лядов В. К., Малихова О. А., Неред С. Н., Проценко С. А., Рябов А. Б., Стилиди И. С., Тер-Ованесов М. Д., Хомяков В. М. (2020) Практические pекомендации по лекарственному лечению рака желудка. Злокачественные опухоли. 10, 339–354.
  64. Muti H.S., Heij L.R., Keller G., Kohlruss M., Langer R., Dislich B., Cheong J.H., Kim Y.W., Kim H., Kook M.C., Cunningham D., Allum W.H., Langley R.E., Nankivell M.G., Quirke P., Hayden J.D., West N.P., Irvine A.J., Yoshikawa T., Oshima T., Huss R., Grosser M., Roviello F., d’Ignazzio A., Quaas A., Alakus H., Tan X., Pearson A.T., Luedde., Ebbert M.P., Jager D., Trautwein C., Gaisa N.T., Grabsch H.I., Kather J.N. (2021) Development and validation of deep learning classifiers to detect Epstein–Barr virus and microsatellite instability status in gastric cancer: a retrospective multicentre cohort study. Lancet. Digital Health. 3, e654–e664.
  65. Ботезату И.В., Панчук И.О., Строганова А.М., Сендерович А.И., Кондратова В.Н., Шелепов В.П., Лихтенштейн А.В. (2017) Сканирование мутаций KRAS, NRAS, BRAF и PIK3CA методом плавления ДНК c использованием зондов TaqMan. Молекуляр. биология. 51, 50–58.

Қосымша файлдар


© А.М. Данишевич, Н.И. Поспехова, А.М. Строганова, Д.А. Головина, М.П. Никулин, А.Е. Калинин, С.Э. Николаев, И.С. Стилиди, Л.Н. Любченко, 2023

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>